EZH2’s role in changing RNA in prostate cancer
A novel role for EZH2 in A-to-I RNA editing in prostate cancer
This project looks at how the protein EZH2 alters RNA editing in prostate cancer to help find new treatment targets for men with advanced disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11251287 on NIH RePORTER |
What this research studies
From a patient point of view, researchers will study how EZH2 changes RNA in prostate tumors and how those changes might make cancers more aggressive or therapy-resistant. They will analyze tumor tissue and molecular data, compare RNA editing patterns, and use laboratory models to trace the mechanisms behind those changes. The team will also test whether targeting EZH2-related pathways or using existing therapies can counteract harmful RNA edits. Results are intended to identify potential targets that could lead to new or improved treatments for prostate cancer patients in the future.
Who could benefit from this research
Good fit: Ideal candidates would be men with advanced, recurrent, or therapy-resistant prostate cancer who might donate tumor tissue, blood samples, or consider future clinical trials based on the findings.
Not a fit: People without prostate cancer or those with very low-risk, localized prostate cancer are unlikely to gain direct benefit from this specific work.
Why it matters
Potential benefit: If successful, this work could reveal new targets or strategies to treat advanced or therapy-resistant prostate cancer.
How similar studies have performed: Prior research has shown EZH2 can drive aggressive cancer behavior and EZH2 inhibitors have activity in some cancers, but linking EZH2 to A-to-I RNA editing in prostate cancer is a newer, less-tested area.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Cao, Qi — Northwestern University
- Study coordinator: Cao, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.